Participant flow

Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma · Source last updated 2018-06-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined (9mg/m2, 12 mg/m2, 15 mg/m2 or 18 mg/m2)

   id

   FG000

   title

   ALL Patients

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         2

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         2

      comment

      Completion defined as those removed from treatment due to disease progression (per protocol)

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Two subjects were ineligible and therefore never started treatment.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice